Diovan
Ex-Novartis employee found not guilty of deceitful drug advertising
March 17, 2017Medical Communications, Sales and Marketing Diovan, Novartis, legal
A Tokyo court has ruled finding ex-Novartis employee Nobuo Shirahashi and the company’s Tokyo-based sales arm Novartis Pharma KK not …
Novartis sales below forecast in ‘transformative’ year
January 28, 2015Sales and Marketing Diovan, Exforge, Gleevec, Jimenez, Novartis, amlodipine, q4, valsartan
Novartis’ fourth quarter sales have faded slightly as growth in pharmaceuticals is beaten back by generic competition, and the firm …
Novartis heart drug sees stellar results
September 1, 2014Sales and Marketing Diovan, LCZ696, Novartis, failure, heart, valsartan
Novartis’ new heart pill has produced stellar results in helping patients with heart failure live longer, making it the first …
Novartis faces data fraud charges in Japan
July 3, 2014Medical Communications, Sales and Marketing Diovan, Japan, Novartis, data, fraud, heart, valsartan
Novartis is facing criminal charges in Japan over the alleged falsifying of data for its once big-selling heart drug Diovan. …
Ranbaxy’s Diovan copycat approved in US
June 27, 2014Manufacturing and Production, Sales and Marketing Diovan, FDA, Novartis, Ranbaxy, blood pressure, sun pharmaceuticals, valsartan
Ranbaxy has won approval for its copycat form of Novartis’ blockbuster blood pressure drug Diovan, as the Swiss firm finally …
Police raid Novartis Tokyo office
February 20, 2014Medical Communications, Sales and Marketing Diovan, Japan, Novartis, tokyo
Authorities in Japan have raided the premises of Novartis’ Tokyo operation as part of an ongoing investigation into the promotion …
Novartis may axe 1,000 jobs in Diovan wake
January 23, 2014Manufacturing and Production, Sales and Marketing Coartem, Diovan, Novartis, cuts
Novartis will shut down a plant in New York State that made heart drug Diovan and malaria treatment Coartem as …
Novartis faces Japan probe
January 10, 2014Sales and Marketing Diovan, Japan, Novartis
Novartis is under pressure in Japan where authorities are looking at the way the Swiss firm promoted its blood pressure …
Novartis sees profit slip
October 23, 2013Sales and Marketing Afinitor, Diovan, Novartis, Q3, gilenya
Novartis saw generic competition erode profit in the third quarter of the year, although sales across the group actually rose …
Diovan trials may have been run by Novartis staff
May 29, 2013Research and Development, Sales and Marketing Diovan, Novartis
Several post-marketing clinical trials of the blockbuster blood pressure drug Diovan may have been run by employees of the drug’s …
Novartis reverses plant closure decision
January 18, 2012Manufacturing and Production, Research and Development, Sales and Marketing Basel, Diovan, Novartis, Nyon, closure, job cuts
Novartis has said it will not close down a plant in Switzerland that had been due for closure, and has …
Novartis to cut 2,000 US jobs
January 13, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Diovan, Novartis, job cuts
Novartis will slash 1,960 jobs in the US as it prepares for life without its blockbuster medicine Diovan. The hypertension …
Takeda’s blood pressure treatment Edarbi approved
December 9, 2011Sales and Marketing Diovan, Eisai, cardiovascular, high blood pressure, hypertension
Takeda’s new hypertension treatment Edarbi has been approved in Europe.Edarbi (azilsartan medoxomil) is a new once-daily angiotensin receptor blocker (ARB) …
European regulator probes ARB cancer link
June 28, 2010Sales and Marketing ARB, Amias, Aprovel, Cozaar, Diovan, Micardis
European regulators have begun an investigation into a possible risk of cancer in patients taking angiotensin II receptor inhibitors for …
Tekturna fails to show heart attack benefit
March 17, 2010Research and Development Diovan, Novartis, Tekturna, hypertension
Novartis’ hypertension treatment Tekturna has failed to show it helps patients recover from a heart attack when added to standard …
Latest content
